You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

ER-Positive

Showing 51 - 75 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Neoadjuvant Treatment for HER2-positive, ER-positive Breast Cancer Trial (palbociclib and exemestane plus trastuzumab and

Not yet recruiting
  • Neoadjuvant Treatment for HER2-positive, ER-positive Breast Cancer
  • palbociclib and exemestane plus trastuzumab and pyrotinib
  • (no location specified)
Apr 23, 2021

ER-positive, HER2-negative Breast Cancer Trial in Ruddington ([14C]AZD9833 Oral Solution, 75 mg)

Completed
  • ER-positive, HER2-negative Breast Cancer
  • [14C]AZD9833 Oral Solution, 75 mg
  • Ruddington, United Kingdom
    Research Site
Jun 24, 2022

ER+, HER2-, Metastatic Breast Cancer Trial in China (AZD9833, AZD9833 with palbociclib, AZD9833 with everolimus)

Recruiting
  • ER+, HER2-, Metastatic Breast Cancer
  • Beijing, China
  • +5 more
Jan 13, 2023

Lateral Malleolus Fracture Trial in Oulu (Non-operative treatment, Surgery)

Active, not recruiting
  • Lateral Malleolus Fracture
  • Non-operative treatment
  • Surgery
  • Oulu, Pohjois-Pohjanmaa, Finland
    OYS, Oulu university hospital, Department of orthopedic and trau
Aug 17, 2022

Breast Cancer Trial in São Paulo (radiation, procedure, other)

Recruiting
  • Breast Cancer
  • Radiotherapy
  • +2 more
  • São Paulo, SP, Brazil
    ICESP
Aug 5, 2022

Personalised Disease Monitoring in Metastatic Breast Cancer

Recruiting
  • Breast Cancer Metastatic
  • Estrogen Receptor-positive Breast Cancer
    • Gothenburg, Sweden
    • +6 more
    Dec 7, 2022

    Endometroid Endometrial Cancer Trial in Baltimore (Alpelisib Pill, Fulvestrant injection)

    Not yet recruiting
    • Endometroid Endometrial Cancer
    • Alpelisib Pill
    • Fulvestrant injection
    • Baltimore, Maryland
      Johns Hopkins Medicine
    Dec 7, 2021

    Breast Cancer, Brain Metastases Trial in Guangzhou (Palbociclib, Trastuzumab, Pyrotinib and Fulvestrant)

    Recruiting
    • Breast Cancer
    • Brain Metastases
    • Palbociclib, Trastuzumab, Pyrotinib and Fulvestrant
    • Guangzhou, Guangdong, China
    • +1 more
    Apr 24, 2022

    Breast Cancer, HER2-positive Breast Cancer, ER Positive Breast Cancer Trial (Neratinib, Letrozole (L) or Anastrozole (A),

    Not yet recruiting
    • Breast Cancer
    • +3 more
    • (no location specified)
    Jan 11, 2022

    Breast Cancer, Solid Tumor, Adult Trial in United States (APG-2575, Palbociclib)

    Recruiting
    • Breast Cancer
    • Solid Tumor, Adult
    • Atlanta, Georgia
    • +3 more
    Aug 12, 2022

    Metastatic Breast Cancer Trial in Dijon (18F Fluoroestradiol Radiopharmaceutical with PET/CT)

    Recruiting
    • Metastatic Breast Cancer
    • 18F Fluoroestradiol Radiopharmaceutical with PET/CT
    • Dijon, France
      CGFL
    Aug 2, 2022

    FES F18 PET/CT in Metastatic Breast Cancer Patients

    Recruiting
    • Metastatic Breast Cancer
    • 18F Fluoroestradiol Radiopharmaceutical with PET/CT
    • Long Beach, California
    • +5 more
    Jan 19, 2023

    Breast Cancer Trial in Denver, Sarasota, Nashville (AC682)

    Recruiting
    • Breast Cancer
    • Denver, Colorado
    • +4 more
    Dec 12, 2022

    Breast Cancer, Hormone Receptor-positive Breast Cancer, Hormone Therapy Trial in Taipei City, Taipei (Palbociclib, Ribociclib,

    Recruiting
    • Breast Cancer
    • +2 more
    • Taipei City, Taiwan
    • +1 more
    Mar 15, 2023

    Breast Cancer Trial in Singapore (Lenvatinib + Letrozole, Fulvestrant)

    Not yet recruiting
    • Breast Cancer
    • Singapore, Singapore
      Nationa University Hospital
    Jan 4, 2022

    Breast Cancer Trial in Beijing (Hemay022+exemestane, Hemay022+letrozole, Hemay022+ fulvestrant)

    Unknown status
    • Breast Cancer
    • Beijing, China
      Beijing Cancer Hospital
    Apr 27, 2021

    Breast Tumor Female Trial in Melbourne (Venetoclax, Palbociclib, Letrozole)

    Recruiting
    • Breast Neoplasm Female
    • Melbourne, Victoria, Australia
    • +2 more
    Mar 10, 2022

    Estrogen-receptor-positive Breast Cancer, HER2/Neu-Negative Breast Cancer, Advanced Breast Cancerv Trial in Chicago

    Not yet recruiting
    • Estrogen-receptor-positive Breast Cancer
    • +3 more
    • elacestrant, palbociclib, abemaciclib, ribociclib
    • Chicago, Illinois
      Northwestern University
    Sep 25, 2023

    Breast Cancer Trial ([68Ga]Ga-NeoB, [177Lu]Lu-NeoB, Ribociclib)

    Not yet recruiting
    • Breast Cancer
    • (no location specified)
    May 22, 2023

    Electronic Medical Record-Based Nudge to Reduce SLNB

    Recruiting
    • Breast Cancer
    • Estrogen-receptor-positive Breast Cancer
    • Column-based nudge in the EHR
    • No column-based nudge in the EHR
    • Pittsburgh, Pennsylvania
      University of Pittsburgh Medical Center
    Aug 17, 2023

    Gene Recurrence Score on Chemotherapy Prescribing in ER

    Active, not recruiting
    • Breast Cancer
      • Letterkenny, Co. Donegal, Ireland
      • +9 more
      Jan 14, 2022

      Breast Cancer Trial in Washington, Baltimore (Outcomes4Me, Semi-structured interview)

      Recruiting
      • Breast Cancer
      • Outcomes4Me
      • Semi-structured interview
      • Washington, District of Columbia
      • +1 more
      Jan 13, 2023

      ER+ HER2- Advanced Breast Cancer Trial in Spain, United Kingdom, United States (AZD9833, AZD9833 with palbociclib, AZD9833 with

      Recruiting
      • ER+ HER2- Advanced Breast Cancer
      • Aurora, Colorado
      • +16 more
      Aug 22, 2022

      Estrogen Receptor-positive Breast Cancer Trial in Nashville (2-Week Ketogenic Diet, Letrozole)

      Recruiting
      • Estrogen Receptor-positive Breast Cancer
      • Nashville, Tennessee
        Vanderbilt-Ingram Cancer Center
      Sep 20, 2022

      Breast Cancer, HER2-negative Breast Cancer, ER Positive Breast Cancer Trial in Stanford (Infigratinib, Tamoxifen, Omnipaque 350)

      Recruiting
      • Breast Cancer
      • +3 more
      • Stanford, California
        Stanford University
      Feb 16, 2022